SLC5A2 and type 2 diabetes mellitus: This study covers the structural and functional properties of SGLT2 in type 2 diabetes, the main classes and characteristics of phytocannabinoids, phytocannabinoids as the SGLT2 inhibitor target, preclinical and clinical studies of phytocannabinoid–SGLT2 interaction, clinical significance and safety of phytocannabinoids for T2DM, limitations and challenges of phytocannabinoids as treatment for T2DM, future research directions, as well as conclusions and perspectives.